Cefoxitin Sodium for Injection
Function and Efficacy
Cefoxitin Sodium for Injection kills bacteria by inhibiting bacterial cell wall synthesis, and due to its structural characteristics, it has a high resistance to β-lactamase produced by bacteria. Some common clinical Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. Cefoxitin Sodium for Injection is resistant to Pseudomonas aeruginosa, most strains of Enterococcus, and Escherichia coli.
Ingredients
The main ingredient of this product is cefoxitin sodium, and its other scientific name is: (6R,7S)-3-carbamoyloxymethyl-7-methoxy-8-oxo-7-[2(2-thienyl)acetylamino]-5-thia-1-azabicyclo-[4.2.0]oct-2-ene-2-carboxylic acid sodium salt.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Cefoxitin sodiumIngredients |
It kills bacteria by inhibiting bacterial cell wall synthesis and has high resistance to β-lactamase produced by bacteria. Some common Gram-positive, Gram-negative aerobic and anaerobic pathogens are highly sensitive to this product. It is resistant to Pseudomonas aeruginosa, most strains of enterococci, and Escherichia coli. More |
33564-30-6 | 23 |
Appearance
This product is white or off-white powder with a slight special odor.
Indication
It is suitable for the following infections caused by bacteria that are sensitive to this product: 1. Upper and lower respiratory tract infections. 2. Urinary tract infections including uncomplicated gonorrhea. 3. Peritonitis and other intra-abdominal and intra-pelvic infections. 4. Sepsis (including typhoid fever). 5. Gynecological infections. 6. Bone and joint soft tissue infections. 7. Endocarditis. Since this product is effective against anaerobic bacteria and stable against β-lactamase, it is particularly suitable for mixed aerobic and anaerobic infections, as well as infections caused by bacteria that produce β-lactamase and are sensitive to this product.
Usage and Dosage
Intramuscular injection, intravenous injection or intravenous drip. The common dosage for adults is 1-2g/time, once every 6-8 hours. Or adjust the dosage according to the sensitivity of the pathogen and the condition. For patients with renal insufficiency, adjust the dosage according to the creatinine clearance rate. This product is used for intramuscular injection, each gram is dissolved in 2ml of 0.5% lidocaine hydrochloride; for intravenous injection, each gram is dissolved in 10ml of sterile water for injection; for intravenous drip, 1-2g of cefoxitin sodium is dissolved in 50ml or 100ml of normal saline or 5% or 10% glucose solution.
Adverse Reactions
The adverse reactions of this product are mild. The most common local reactions: thrombophlebitis may occur after intravenous injection, and local induration and tenderness may occur after intramuscular injection. In addition, allergic reactions (rash, itching, eosinophilia, fever, dyspnea, etc.), hypotension, diarrhea, nausea, vomiting, leukopenia, thrombocytopenia, anemia, and transient increases in ALT, AST, ALP, LDH, BUN or serum Cr values are occasionally seen.
Precautions
Patients who are allergic to this product and cephalosporin antibiotics are contraindicated.
Drug Interactions
Not yet clear.
Storage
Keep in a dark and airtight container in a cool and dry place. Validity period: 24 months
Packaging Specification
1.0g (calculated as cefoxitin)
Validity Period
24 months.
Manufacturer
Shenzhen Salubris Pharmaceuticals Co., Ltd.
-
Founded in:
1998-11-03 -
Address:
Area A, 4th Floor, Digital Peninsula, No. 289, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen -
Tax NO.:
91440300708453259J -
Registered Funds:
1,114.816535 yuan -
Website:
-
Email: